Ikarian Capital, LLC Reata Pharmaceuticals Inc Put Options Transaction History

Ikarian Capital, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $4.05 Million - $7.7 Million	182,800 Added 993.48%	201,200 $7.64 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $357,144 - $671,416	18,400 New	18,400 $463,000
Q1 2022 May 13, 2022	BUY	$24.12 - $39.6 $13.3 Million - $21.8 Million	549,600 Added 549.6%	649,600 $21.3 Million
Q4 2021 Feb 14, 2022	SELL	$25.61 - $110.96 $9.51 Million - $41.2 Million	-371,400 Reduced 78.79%	100,000 $2.64 Million
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $29.7 Million - $42.4 Million	296,500 Added 169.53%	471,400 $47.4 Million
Q2 2021 Aug 16, 2021	BUY	$78.27 - $151.29 $5.48 Million - $10.6 Million	70,000 Added 66.73%	174,900 $24.8 Million
Q1 2021 May 17, 2021	SELL	$94.25 - $132.81 $5.82 Million - $8.19 Million	-61,700 Reduced 37.03%	104,900 $10.5 Million
Q4 2020 Feb 12, 2021	BUY	$102.03 - $184.62 $11.1 Million - $20.2 Million	109,200 Added 190.24%	166,600 $20.6 Million
Q3 2020 Nov 16, 2020	SELL	$93.53 - $163.34 $2.46 Million - $4.3 Million	-26,300 Reduced 31.42%	57,400 $5.59 Million
Q2 2020 Aug 14, 2020	SELL	$126.3 - $176.56 $5.22 Million - $7.29 Million	-41,300 Reduced 33.04%	83,700 $13.1 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $15.5 Million - $31 Million	125,000 New	125,000 $18 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.